Amneal Pharmaceuticals (AMRX) Net Cash Flow (2017 - 2026)

Amneal Pharmaceuticals' Net Cash Flow history runs 10 years deep, the most recent figure standing at -$107.5 million for Q1 2026.

• On a quarterly basis, Net Cash Flow fell 116.94% year-over-year to -$107.5 million in Q1 2026; TTM through Mar 2026 was $138.2 million, a 664.6% increase from a year earlier, with the FY2025 full-year figure at $196.2 million, up 865.93% from the prior year.
• Net Cash Flow fell to -$107.5 million in Q1 2026 per AMRX's latest filing, from $74.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $155.4 million in Q3 2025 and bottomed at -$118.4 million in Q2 2022.
• The 5-year median for Net Cash Flow is -$1.9 million (2022), against an average of -$2.5 million.
• Across the five-year window, Net Cash Flow slumped 885.96% in 2023 and surged 1137.19% in 2024, its largest moves.
• Year by year, Net Cash Flow stood at -$56.9 million in 2022, then jumped by 105.8% to $3.3 million in 2023, then jumped by 1137.19% to $40.8 million in 2024, then surged by 83.12% to $74.7 million in 2025, then sank by 243.84% to -$107.5 million in 2026.
• Per Business Quant, the three latest AMRX Net Cash Flow figures stand at -$107.5 million (Q1 2026), $74.7 million (Q4 2025), and $155.4 million (Q3 2025).